Performance Evaluation of a Colorectal Cancer-Associated MassARRAY-Based Hotspot Genotyping Assay for KRAS, NRAS, BRAF, and PIK3CA Using Solid Tumor Specimens
Frontiers in Bioscience-Landmark · 23.07.2026 · 31 (7)
DOI: 10.31083/fbl53019 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Bioscience-Landmark, online erschienen am 23.07.2026. Verfasst von Vishakha Vashisht und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Augusta University, Augusta, GA 30909, USA. Hauptthemen laut MEDLINE: Proto-Oncogene Proteins B-raf, Colorectal Neoplasms, Class I Phosphatidylinositol 3-Kinases, Proto-Oncogene Proteins p21(ras). Die Arbeit nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Agena Biosciences.
Abstract (Originalsprache)
Background:Accurate identification of actionable somatic variants is essential for therapeutic stratification in colorectal cancer (CRC). While next-generation sequencing (NGS) enables comprehensive genomic profiling, targeted approaches may provide faster and more practical alternatives for routine diagnostics.Methods:This study evaluated the analytical performance of the Agena Bioscience iPLEX® High Sensitivity (HS) Colon Panel using MassARRAY MALDI-TOF technology for detection of hotspot variants in KRAS, NRAS, BRAF, and PIK3CA from formalin-fixed paraffin-embedded (FFPE) specimens. A total of 60 unique clinical and reference samples were analyzed, targeting 26 single-nucleotide variants and compared with an orthogonal targeted NGS assay. Limit of detection (LOD) was assessed using serial dilutions of reference materials, and intra- and inter-run reproducibility was evaluated across multiple runs. Analytical performance metrics including positive and negative percent agreement, predictive values, and error rates were calculated.Results:The assay demonstrated complete concordance with NGS across all evaluated variants, requiring only 20 ng of DNA input, compared to 80–120 ng for a successful NGS run. LOD studies showed reliable detection of multiple variants at approximately 5% variant allele frequency, with BRAF p.V600E detectable near 1%. Intra- and inter-run analyses achieved 100% concordance, confirming assay reproducibility. Aggregated performance metrics demonstrated high sensitivity and specificity across a heterogeneous sample set.Conclusions:These findings establish the iPLEX® HS Colon Panel as a reliable platform for rapid detection of clinically actionable hotspot mutations. This study represents analytical validation using mixed FFPE tumor specimens; evaluation in larger colorectal cancer cohort, is warranted.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology, Augusta University, Augusta, GA 30909, USA.
Förderung
- Agena Biosciences
Zitieren
APA
Vashisht, V., Vashisht, A., Mondal, A. K., Ahluwalia, P. K., Farmaha, J., Woodall, J., & Kolhe, R. (2026). Performance Evaluation of a Colorectal Cancer-Associated MassARRAY-Based Hotspot Genotyping Assay for KRAS, NRAS, BRAF, and PIK3CA Using Solid Tumor Specimens. Frontiers in Bioscience-Landmark, 31(7). https://doi.org/10.31083/fbl53019
Vancouver
Vashisht V, Vashisht A, Mondal AK, Ahluwalia PK, Farmaha J, Woodall J, et al. Performance Evaluation of a Colorectal Cancer-Associated MassARRAY-Based Hotspot Genotyping Assay for KRAS, NRAS, BRAF, and PIK3CA Using Solid Tumor Specimens. Frontiers in Bioscience-Landmark. 2026;31(7). doi:10.31083/fbl53019
BibTeX
@article{Vashisht2026,
author = {Vashisht, Vishakha and Vashisht, Ashutosh and Mondal, Ashis K and Ahluwalia, Pankaj K and Farmaha, Jaspreet and Woodall, Jana and Kolhe, Ravindra},
title = {Performance Evaluation of a Colorectal Cancer-Associated MassARRAY-Based Hotspot Genotyping Assay for KRAS, NRAS, BRAF, and PIK3CA Using Solid Tumor Specimens},
journal = {Frontiers in Bioscience-Landmark},
year = {2026},
volume = {31},
number = {7},
doi = {10.31083/fbl53019}
}
EUVIMED